. 2022 Jan 25;13(6):647–675. doi: 10.1039/d2md00009a

Summary of clinical trials of different monoclonal antibodies on COVID-19 patients.

Monoclonal antibodies	NCT No.	Title	Clinical trial status	Sample	Study area	Phase
Sarilumab (IL-6 receptors (sIL-6R and mIL-6R) inhibitor)	NCT04315298	Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19	Active, not recruiting	1912	USA	III
	NCT04315298	https://clinicaltrials.gov/ct2/show/NCT04315298	Active, not recruiting	1912	USA	III
	NCT04324073	Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients – sarilumab trial – CORIMUNO-19 – SARI (CORIMUNO-SARI)	Active, not recruiting		France	III
	NCT04324073	https://clinicaltrials.gov/ct2/show/NCT04324073	Active, not recruiting		France	III
	NCT04327388	Sarilumab COVID-19	Active, not recruiting		Canada	III
	NCT04327388	https://clinicaltrials.gov/ct2/show/NCT04327388	Active, not recruiting		Canada	III
	NCT02735707	Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP)	Recruiting		Australia	IV
	NCT02735707	https://clinicaltrials.gov/ct2/show/NCT02735707	Recruiting		Australia	IV
	NCT04345289	Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP)	Recruiting		Denmark	III
	NCT04345289	https://clinicaltrials.gov/ct2/show/NCT04345289	Recruiting		Denmark	III
Olokizumab	NCT04380519	Study of the efficacy and safety of a single administration of olokizumab and RPH-104 with standard therapy in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)	Recruiting	372	Russian Federation	III
Olokizumab	NCT04380519	https://clinicaltrials.gov/ct2/show/NCT04380519	Recruiting	372	Russian Federation	III
Levilimab	NCT04397562	A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 (CORONA)	Active, not recruiting	206	Russian Federation	III
Levilimab	NCT04397562	https://clinicaltrials.gov/ct2/show/NCT04397562	Active, not recruiting	206	Russian Federation	III
Lenzilumab (GM-CSF inhibitor)	NCT04351152	Phase 3 study to evaluate the efficacy and safety of lenzilumab in hospitalized patients with COVID-19 pneumonia	Recruiting	520	USA	III
Lenzilumab (GM-CSF inhibitor)	NCT04351152	https://clinicaltrials.gov/ct2/show/NCT04351152	Recruiting	520	USA	III
Mavrilimumab	NCT04447469	Study of mavrilimumab (KPL-301) in participants hospitalized with severe corona virus disease 2019 (COVID-19) pneumonia and hyper-inflammation	Recruiting	588	USA	III
Mavrilimumab	NCT04447469	https://clinicaltrials.gov/ct2/show/NCT04447469	Recruiting	588	USA	III
37Canakinumab (IL-1β blocker)	NCT04362813	Study of the efficacy and safety of canakinumab treatment for CRS in participants with COVID-19-induced pneumonia (CAN-COVID)	Recruiting	451	USA	III
37Canakinumab (IL-1β blocker)	NCT04362813	https://clinicaltrials.gov/ct2/show/NCT04362813	Recruiting	451	USA	III
REGN10933 REGN10987 combination therapy	NCT04452318	Study assessing the efficacy and safety of anti-spike SARS CoV-2 monoclonal antibodies for prevention of SARS CoV-2	Recruiting	3750	USA	III
		Infection asymptomatic in healthy adults who are household contacts to an individual with a positive SARSCoV-2 RT-PCR assay
		https://clinicaltrials.gov/ct2/show/NCT04452318
Anakinra	NCT04324021	Efficacy and safety of emapalumab and anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 infection	Recruiting	16	Italy	III
Anakinra	NCT04324021	https://clinicaltrials.gov/ct2/show/NCT04324021	Recruiting	16	Italy	III
Emapalumab	NCT04324021	Efficacy and safety of emapalumab and anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 infection	Recruiting	16	Italy	III
Emapalumab	NCT04324021	https://clinicaltrials.gov/ct2/show/NCT04324021	Recruiting	16	Italy	III
Ravulizumab	NCT04390464	mulTi-arm therapeutic study in pre-ICU patients admitted with Covid-19 – repurposed drugs (TACTIC-R) (TACTIC-R)	Recruiting	1167	UK	III
Ravulizumab	NCT04390464	https://clinicaltrials.gov/ct2/show/NCT04390464	Recruiting	1167	UK	III
Bamlanivimab	NCT04701658	A real world study of bamlanivimab in participants with mild-to-moderate coronavirus disease 2019 (COVID-19) (BLAZE-5)	Completed	109	USA	II
Casirivimab + imdevimab	NCT05092581	COVID-19 study of pharmacokinetics, safety, tolerability, and efficacy of intravenous anti-spike(s) SARS-CoV-2 monoclonal antibodies (casirivimab + imdevimab) for the treatment of pediatric patients hospitalized due to COVID-19	Active, not recruiting	40	USA	I
Bamlanivimab and etesevimab or LY3832479 (LY-CoV016)	NCT04497987	A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2)	Completed	1374	USA	III